196 related articles for article (PubMed ID: 24178448)
1. Biochemical and quality of life responses to octreotide-LAR in acromegaly.
Mangupli R; Camperos P; Webb SM
Pituitary; 2014 Dec; 17(6):495-9. PubMed ID: 24178448
[TBL] [Abstract][Full Text] [Related]
2. Change in quality of life in patients with acromegaly after treatment with octreotide LAR: first application of AcroQoL in Korea.
Chin SO; Chung CH; Chung YS; Kim BJ; Kim HY; Kim IJ; Kim JG; Kim MS; Kim SY; Lee EJ; Lee KY; Kim SW
BMJ Open; 2015 Jun; 5(6):e006898. PubMed ID: 26063564
[TBL] [Abstract][Full Text] [Related]
3. Cardiovascular effects of depot long-acting somatostatin analog Sandostatin LAR in acromegaly.
Colao A; Marzullo P; Ferone D; Spinelli L; Cuocolo A; Bonaduce D; Salvatore M; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2000 Sep; 85(9):3132-40. PubMed ID: 10999798
[TBL] [Abstract][Full Text] [Related]
4. Sandostatin LAR in acromegaly: a 6-week injection interval suppresses GH secretion as effectively as a 4-week interval.
Biermasz NR; van den Oever NC; Frölich M; Arias AM; Smit JW; Romijn JA; Roelfsema F
Clin Endocrinol (Oxf); 2003 Mar; 58(3):288-95. PubMed ID: 12608933
[TBL] [Abstract][Full Text] [Related]
5. Short- and long-term changes of quality of life in patients with acromegaly: results from a prospective study.
Sardella C; Lombardi M; Rossi G; Cosci C; Brogioni S; Scattina I; Webb SM; Gasperi M; Martino E; Bogazzi F
J Endocrinol Invest; 2010 Jan; 33(1):20-5. PubMed ID: 20203538
[TBL] [Abstract][Full Text] [Related]
6. Time course of GH and IGF-1 levels following withdrawal of long-acting octreotide in acromegaly.
Lorcy Y; Dejager S; Chanson P;
Pituitary; 2000 Nov; 3(3):193-7. PubMed ID: 11383486
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution.
Jallad RS; Musolino NR; Salgado LR; Bronstein MD
Clin Endocrinol (Oxf); 2005 Aug; 63(2):168-75. PubMed ID: 16060910
[TBL] [Abstract][Full Text] [Related]
8. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQoL: a 6-month prospective study.
Webb SM; Badia X; Surinach NL;
Eur J Endocrinol; 2006 Aug; 155(2):269-77. PubMed ID: 16868140
[TBL] [Abstract][Full Text] [Related]
9. Investigation into the efficacy and safety of octreotide LAR in Japanese patients with acromegaly: Shizuoka study.
Oki Y; Inoue T; Imura M; Tanaka T; Genma R; Iwabuchi M; Hataya Y; Matsuzawa Y; Iino K; Nishizawa S; Nakamura H
Endocr J; 2009; 56(9):1095-101. PubMed ID: 19755754
[TBL] [Abstract][Full Text] [Related]
10. Does partial surgical tumour removal influence the response to octreotide-LAR in acromegalic patients previously resistant to the somatostatin analogue?
Jallad RS; Musolino NR; Kodaira S; Cescato VA; Bronstein MD
Clin Endocrinol (Oxf); 2007 Aug; 67(2):310-5. PubMed ID: 17555503
[TBL] [Abstract][Full Text] [Related]
11. [Comparison between integrated 24-hour concentrations of growth hormone, insulin-like growth factor I and prolactin in acromegalic patients treated with octreotide and patients treated with octreotide LAR].
Esposito V; Esposito D; Lo Iudice G
Minerva Endocrinol; 2001 Dec; 26(4):289-92. PubMed ID: 11782718
[TBL] [Abstract][Full Text] [Related]
12. Octreotide long-acting release (LAR): a review of its use in the management of acromegaly.
McKeage K; Cheer S; Wagstaff AJ
Drugs; 2003; 63(22):2473-99. PubMed ID: 14609359
[TBL] [Abstract][Full Text] [Related]
13. Comparison of monthly intramuscular injections of Sandostatin LAR with multiple subcutaneous injections of octreotide in the treatment of acromegaly; effects on growth hormone and other markers of growth hormone secretion.
Hunter SJ; Shaw JA; Lee KO; Wood PJ; Atkinson AB; Bevan JS
Clin Endocrinol (Oxf); 1999 Feb; 50(2):245-51. PubMed ID: 10396369
[TBL] [Abstract][Full Text] [Related]
14. The value of an acute octreotide suppression test in predicting long-term responses to depot somatostatin analogues in patients with active acromegaly.
Karavitaki N; Botusan I; Radian S; Coculescu M; Turner HE; Wass JA
Clin Endocrinol (Oxf); 2005 Mar; 62(3):282-8. PubMed ID: 15730408
[TBL] [Abstract][Full Text] [Related]
15. Impaired quality of life of patients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance.
Matta MP; Couture E; Cazals L; Vezzosi D; Bennet A; Caron P
Eur J Endocrinol; 2008 Mar; 158(3):305-10. PubMed ID: 18299462
[TBL] [Abstract][Full Text] [Related]
16. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
[TBL] [Abstract][Full Text] [Related]
17. Treatment of acromegaly improves quality of life, measured by AcroQol.
Paisley AN; Rowles SV; Roberts ME; Webb SM; Badia X; Prieto L; Shalet SM; Trainer PJ
Clin Endocrinol (Oxf); 2007 Sep; 67(3):358-62. PubMed ID: 17555502
[TBL] [Abstract][Full Text] [Related]
18. Octreotide LAR treatment of acromegaly in "real life": long-term outcome at a tertiary care center.
Espinosa-de-los-Monteros AL; Gonzalez B; Vargas G; Sosa E; Mercado M
Pituitary; 2015 Jun; 18(3):290-6. PubMed ID: 24781039
[TBL] [Abstract][Full Text] [Related]
19. Long-term effects of depot long-acting somatostatin analog octreotide on hormone levels and tumor mass in acromegaly.
Colao A; Ferone D; Marzullo P; Cappabianca P; Cirillo S; Boerlin V; Lancranjan I; Lombardi G
J Clin Endocrinol Metab; 2001 Jun; 86(6):2779-86. PubMed ID: 11397887
[TBL] [Abstract][Full Text] [Related]
20. Predicting therapeutic response and degree of pituitary tumour shrinkage during treatment of acromegaly with octreotide LAR.
Jenkins PJ; Emery M; Howling SJ; Evanson J; Besser GM; Monson JP
Horm Res; 2004; 62(5):227-32. PubMed ID: 15477693
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]